CJC Ipamorelin Blend – Premium Research Peptide

What Is Ipamorelin?

CJC Ipamorelin refers to a synergistic peptide combination comprising CJC-1295 (a growth hormone-releasing hormone analog) and Ipamorelin (a selective ghrelin receptor agonist). This blend represents a dual-pathway approach to growth hormone (GH) axis research, targeting both the GHRH and ghrelin receptor systems simultaneously .

The CJC Ipamorelin blend capitalizes on two distinct mechanisms: CJC-1295 without DAC (Mod GRF 1-29) binds selectively to GHRH receptors on anterior pituitary somatotrophs, initiating adenylate cyclase activation and promoting the synthesis and release of endogenous GH. Its shorter half-life of approximately 30 minutes allows for a more natural, pulsatile pharmacokinetic profile. Ipamorelin, on the other hand, acts on the ghrelin receptor (GHS-R1a) to trigger the rapid release of stored GH .

A landmark 1990 study by Bowers and colleagues in the Journal of Clinical Endocrinology and Metabolism demonstrated that combining GHRP with GHRH produced synergistic GH responses exceeding the sum of either alone . This foundational finding established the rationale for combining GHRH analogs like CJC-1295 with ghrelin mimetics like Ipamorelin.

---

Product Specifications

---

Research Applications

Growth Hormone Axis Modulation

CJC Ipamorelin provides researchers with a tool for investigating the hypothalamic-pituitary-somatotropic axis. The GHRH pathway (via CJC-1295) stimulates GH synthesis, while the ghrelin pathway (via Ipamorelin) triggers the rapid release of stored GH. Their simultaneous activation produces a synergistic GH pulse that is substantially larger than what either compound can produce alone .

Pulsatile GH Secretion Studies

CJC-1295 (without DAC) has a short half-life that supports a pharmacokinetic profile closer to endogenous pulsatility . This is significant because continuous GH elevation tends to produce more insulin resistance and receptor downregulation than pulsatile release. The CJC Ipamorelin combination preserves pulsatile GH secretion while enhancing pulse amplitude.

Selective GH Release

Ipamorelin’s defining characteristic among GH secretagogues is its selectivity profile. A 1998 preclinical paper by Raun and colleagues in the European Journal of Endocrinology demonstrated that Ipamorelin released GH at levels comparable to GHRP-6 but without the cortisol, prolactin, or ACTH release that earlier secretagogues produced . This makes the CJC Ipamorelin combination valuable for research requiring GH axis specificity.

Metabolism and Body Composition

Research involving CJC Ipamorelin typically investigates IGF-1 tracking as the primary downstream effector of pulsatile GH release. Sustained GH elevation promotes lipolysis via hormone-sensitive lipase activation and enhances muscle protein synthesis through mTOR and PI3K/Akt pathways .

---

Quality and Purity

Each batch of CJC Ipamorelin undergoes rigorous quality control testing to ensure:

• ≥99% purity verified by HPLC

• Correct molecular weight confirmed by mass spectrometry

• Consistent peptide content validated by amino acid analysis

Certificates of Analysis (COA) are available upon request, providing full transparency for research applications.

---

Frequently Asked Questions

What is CJC Ipamorelin?

CJC Ipamorelin is a synergistic peptide combination of CJC-1295 (a GHRH analog) and Ipamorelin (a ghrelin receptor agonist) used for research into growth hormone axis modulation.

How does CJC Ipamorelin work?

CJC Ipamorelin targets two distinct pituitary receptor systems: CJC-1295 stimulates GH synthesis via GHRH receptors, while Ipamorelin triggers rapid GH release via ghrelin receptors. This dual-pathway approach produces a synergistic GH pulse .

Is CJC Ipamorelin FDA-approved?

No.Ipamorelin is a research peptide supplied for in-vitro laboratory use only. It is not approved by the FDA for human consumption, diagnostic, therapeutic, or clinical use .

What purity level can I expect?

Our CJC Ipamorelin blend is provided at ≥99% purity, verified by HPLC.

How should CJC Ipamorelin be stored?

Ipamorelin should be stored at -20°C for long-term stability. Lyophilised powder should be reconstituted according to standard laboratory protocols.

What is the difference between CJC-1295 with and without DAC?

CJC-1295 without DAC (Drug Affinity Complex) has a shorter half-life of approximately 30 minutes, supporting a more natural pulsatile pharmacokinetic profile. CJC-1295 with DAC extends the half-life to about a week. The CJC Ipamorelin blend typically uses the no-DAC variant .

---

References

• PubMed: Ghrelin and growth hormone secretagogues, physiological and pharmacological aspect – Overview of GHS receptor and ghrelin pathway

• PubMed: Natural and synthetic growth hormone secretagogues – Therapeutic potential of GHSs

• Sage Journals: Injectable Peptide Therapy Primer – CJC-1295 and Ipamorelin in orthopaedic research

• Springer: npj Aging – Short peptides role in senescence – Peptide therapeutic modalities

• ScienceDirect: Growth hormone secretagogues – GHS-R cloning and ghrelin discovery

---

Conclusion

CJC Ipamorelin is a synergistic peptide combination for researchers investigating the growth hormone axis, pulsatile GH secretion, and metabolic pathways. By targeting both GHRH and ghrelin receptor systems, this blend enables studies on GH modulation, IGF-1 tracking, and body composition research.

For researchers requiring a reliable, high-purity peptide blend for growth hormone research, CJC Ipamorelin provides a precise and well-characterized research tool.

---

Ready to Advance Your Research?

Order premium CJC Ipamorelin for your research today. Contact our team for COA requests or technical inquiries.

Call to Action: Shop CJC Ipamorelin Now

Contact Our Research Team